Indole Propionic Acid (IPA), A Gut Microbiota-Derived Metabolite, in Active Pulmonary Tuberculosis (TB) Infection: A Case Control Study
A Case Control Study
DOI:
https://doi.org/10.48048/tis.2024.8499Keywords:
Tuberculosis, Tryptophan, Gut Microbiota, Indole Propionic AcidAbstract
Introduction: A metabolomics study revealed that the tryptophan (Trp) pathway is upregulated in tuberculosis (TB) infection. Indole propionic acid (IPA) is a gut microbiota-derived tryptophan metabolite with antimycobacterial properties through TrpE inhibition and as ligand for AhR in in vitro and in vivo studies. TB infection is associated with gut dysbiosis. However, plasma IPA levels and related factors in active TB patients have not yet been explored. This study aimed to determine the differences and correlations between plasma IPA levels and patient characteristics (age, gender, BMI and GeneXpert result), IPA-producing gut microbiota (Clostridium sporogenes, Lactobacillus sp., and Peptostreptococcus anaerobius), and IFN-γ concentrations in active TB patients and healthy subjects. Materials and methods: A case-control study was performed in 29 active TB patients and 30 healthy controls (HCs) in Aceh, Indonesia. The plasma IPA and IFN-γ levels were measured by ELISA, and the relative abundance of gut microbiota was determined by quantitative PCR (qPCR). The results and discussion: Increased plasma IPA levels (median (IQR) of 22.2 pmol/L (21.3 - 23.9) vs. 18.9 pmol/L (17 - 22.8), p 0.000) were associated with active TB according to the adjusted model (AOR 1.36 (95 % CI 0.37 - 5.1)). Increase of plasma IPA level in higher mycobacterial load patients was found. Higher plasma IPA was positively associated with female, normo- and overweight status, and higher relative abundance of C. sporogenes. The metabolite could be used to discriminate active TB disease at a cutoff of 21.40 pmol/L (72 % sensitivity, 70 % specificity and AUC 0.77). Dysbiosis in IPA-producing bacteria was showed in active TB patients. Conclusion: Plasma IPA could be considered as TB biomarker, and it may also influence disease progression. Future works are needed to validate plasma IPA as biomarker in LTBI and other respiratory infection, as well as its role as biomarker of treatment monitoring response.
HIGHLIGHTS
- The upregulation of the tryptophan (Trp) pathway in tuberculosis infection.
- Indole propionic acid (IPA) is a Trp metabolite with antimycobacterial properties
- Higher plasma IPA levels were found in TB patients than in healthy subjects.
- Dysbiosis of several IPA-producing gut microbiota was revealed in this study.
GRAPHICAL ABSTRACT
Downloads
References
World Health Organization, Available at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022, accessed October 2022.
D Goletti, E Petruccioli, SA Joosten and THM Ottenhofff. Tuberculosis biomarkers: From diagnosis to protection. Infect. Dis. Rep. 2016; 8, 6568.
JM Collins, A Siddiqa, DP Jones, K Liu, RR Kempker, A Nizam, NS Shah, N Ismail, SG Ouma, N Tukvadze, S Li, CL Day, J Rengarajan, JC Brust, NR Gandhi, JD Ernst, HM Blumberg and TR Ziegler. Tryptophan catabolism reflects disease activity in human tuberculosis. JCI Insight 2020; 5, e1377131.
US Gautam, TW Foreman, AN Bucsan, AV Veatch, X Alvarez, T Adekambi, NA Goolden, KM Gentry, LA Doyle-Meyers, KE Russell-Lodrigue, PJ Didier, JL Blanchard, KG Kousoulas, AA Lackner, D Kalman, J Rengarajan, SA Khader, D Kaushal and S Mehra. In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 2018; 115, E62-E71.
EB Bolajoko, OG Arinola, GN Odaibo and M Maiga. Plasma levels of tumor necrosis factor-alpha, interferon-gamma, inducible nitric oxide synthase, and 3-nitrotyrosine in drug-resistant and drug-sensitive pulmonary tuberculosis patients, Ibadan, Nigeria. Int. J. Mycobacteriol. 2020; 9, 185-9.
SM Thomas, LF Garrity, CR Brandt, CS Schobert, GS Feng,MW Taylor, JM Carlin and GI Byrne. IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular chlamydia spp. or toxoplasma growth. J. Immunol. 1993; 150, 5529-34.
K Peng and DM Monack. Indoleamine 2,3-dioxygenase 1 is a lung-specific innate immune defense mechanism that inhibits growth of Francisella tularensis tryptophan auxotrophs. Infect. Immun. 2010; 78, 2723-33.
T Parish. Starvation survival response of mycobacterium tuberculosis. J. Bacteriol. 2003; 185, 6702-6.
VD Mello, J Paananen, J Lindstrom, MA Lankinen, L Shi, J Kuusisto, J Pihlajamaki, S Auriola, M Lehtonen, O Rolandsson, IA Bergdahl, E Nordin, P Ilanne-Parikka, S Keinanen-Kiukaanniemi, R Landberg, JG Eriksson, J Tuomilehto, K Hanhineva and M Uusitupa. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the finnish diabetes prevention study. Sci. Rep. 2017; 7, 46337.
DA Negatu, Y Yamada, Y Xi, ML Go, M Zimmerman, U Ganapathy, V Dartois, M Gengenbacher and T Dick. Gut microbiota metabolite indole propionic acid targets tryptophan biosynthesis in mycobacterium tuberculosis. mBio 2019; 10, e02781-18.
C Gutierrez-Vazquez and FJ Quintana. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity 2018; 48, 19-33.
T Zelante, RG Iannitti, C Cunha, AD Luca, G Giovaannini, G Pieraccini, R Zecchi, C D’Angelo, C Massi-Benedetti, F Fallrino, A Carvalh, P Puccetti and L Romani. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013; 39, 372-85.
V Rothhammer, ID Mascanfroni, L Bunse, MC Takenaka, JE Kenison, L Mayo, C Chao, B Patel, R Yan, M Blain, JI Alvarez, H Kebir, N Anandasabapathy, G Izquierdo, S Jung, N Obholzer, N Pchet, CB Clish, M Prinz, A Prat, …, FJ Quintana. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 2016; 22, 586-97.
P Moura-Alves, K Fae, E Houthuys, A Dorhoi, A Kreuchwig, J Furkert, N Barison, A Diehl, A Munder, P Constant, T Skrahina, U Guhlich-Bornhof, M Klemm, A Koehler, S Bandermann, C Goosmann, H Mollenkopf, R Hurwitz, V Brinkmann, S Fillatreau, …, SHE Kaufmann. AhR sensing of bacterial pigments regulates antibacterial defence. Nature 2014; 512, 387-92.
M Luo, Y Liu, P Wu, D Luo, Q Sun, H Zheng, R Hu, SJ Pandol, Q Li, Y Han and Y Zeng. Alternation of gut microbiota in patients with pulmonary tuberculosis. Front. Physiol. 2017; 8, 822.
C Zhang, M Li, M Lyu, Y Zhou, Y Wang, L You, T Liu, W Peng, H Bai, Z Zhao and B Ying. Exploring the relationship between tuberculosis and gut microbiota: A multi-omics approach. Research Square, North Carolina, 2024.
HS Khan, VR Nair, CR Ruhl, S Alvarez-Arguedas, JLG Rendiz, LH Franco, L Huang, PW Shaul, J Kim, Y Xie, RB Mitchell and MU Shiloh. Identification of scavenger receptor B1 as the airway microfold cell receptor for Mycobacterium tuberculosis. Elife 2020; 9, e53551.
HGHJ Heilig, EG Zoetendal, EE Vaughan, P Marteau, ADL Akkermans and WMD Vos. Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl. Environ. Microbiol. 2002; 68, 114-23.
J Walter, C Hertel, GW Tannock, CM Lis, K Munro and WP Hammes. Detection of lactobacillus, pediococcus, leuconostoc, and weissella species in human feces by using group-specific pcr primers and denaturing gradient gel electrophoresis. Appl. Environ. Microbiol. 2001; 67, 2578-85.
PM Riggio, A Lennon, DJ Taylor and D Bennett. Molecular identification of bacteria associated with canine periodontal disease. Vet. Microbiol. 2011; 150, 394-400.
J Walter, GW Tannock, A Tilsala-Timisjarvi, S Rodtong, DM Loach, K Munro and T Alatossava. Detection and identification of gastrointestinal lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl. Environ. Microbiol. 2000; 66, 297-303.
KJ Livak and TD Schmittgen. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(-Delta Delta C(T)) method. Methods 2001; 25, 402-8.
B Navidshad, JB Liang and MF Jahromi. Correlation coefficients between different methods of expressing bacterial quantification using real time PCR. Int. J. Mol. Sci. 2012; 13, 2119-32.
X Liu. Classification accuracy and cut point selection. Stat. Med. 2012; 31, 2676-86.
AT Dang and BJ Marsland. Microbes, metabolites, and the gut-lung axis. Mucosal Immunol. 2019; 12, 843-50.
J Weiner, J Maertzdorf, JS Sutherland, FJ Duffy, E Thompson, S Suliman, G McEwen, B Thiel, SK Parida, J Zyla, WA Hanekom, RP Mohney, WH Boom, H Mayanja-Kizza, R Howe, HM Dockrell, THM Ottenhoff, TJ Scriba, DE Zak, G Walzl, …, G Consortium. Metabolite changes in blood predict the onset of tuberculosis. Nat. Commun. 2018; 9, 5208.
P Konopelski and Mogilnicka. Biological Effects of indole-3-propionic acid, a gut microbiota-derived metabolite, and its precursor tryptophan in mammals’ health and disease. Int. J. Mol. Sci. 2022; 23, 1222.
DA Negatu, M Gengenbacher, V Dartois and T Dick. Indole propionic acid, an unusual antibiotic produced by the gut microbiota, with anti-inflammatory and antioxidant properties. Front. Microbiol. 2020; 11, 575586.
CG Adu-Gyamfi, T Snyman, L Makhathini, K Otwombe, F Darboe, A Penn-Nicholson, M Fisher, D Savulescu, C Hoffmann, R Chaisson, N Martinson, TJ Scriba, JA George and MS Suchard. Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis. Int. J. Infect. Dis. 2020; 99, 441-8.
N Khan, L Mendonca, A Dhariwal, G Fontes, D Menzies, J Xia, M Divagahi and IL King. Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis. Mucosal Immunol. 2019; 12, 772-83.
Y Hu, Q Yang, B Liu, J Dong, L Sun, Y Zhu, H Su, J Yang, F Yang, X Chen and Q Jin. Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs. J. Infect. 2019; 78, 317-22.
N Khan, A Vidyarthi, S Nadeem, S Negi, G Nair and JN Agrewala. Alteration in the gut microbiota provokes susceptibility to tuberculosis. Front. Immunol. 2016; 7, 529.
Q Zhuo, X Zhang, K Zhang, C Chen, Z Huang and Y Xu. The gut and lung microbiota in pulmonary tuberculosis: Susceptibility, function, and new insights into treatment. Exp. Rev. Anti Infect. Ther. 2023; 21, 1355-64.
J Wen and J He. The Causal impact of the gut microbiota on respiratory tuberculosis susceptibility. Infect. Dis. Ther. 2023; 12, 2535-44.
T Ichinohe, IK Pang, Y Kumamoto, DR Peaper, JH Ho, TS Murray and A Iwasaki. Microbiota regulates immune defense against respiratory tract influenza a virus infection. Proc. Natl. Acad. Sci. U. S. A. 2011; 108, 5354-9.
A Koliada, G Syzenko, V Moseiko, L Budovska, K Puchkov, V Perederiy, Y Gavalko, A Dorofeyev, M Romanenko, S Tkach, L Sineok, O Lushchak and A Vaiserman. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. 2017; 17, 120.
KA Krautkramer, J Fan and Backhed. Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 2021; 19, 77-94.
M Wlodarska, C Luo, R Kolde, E D'Hennezel, JW Annand, CE Heim, P Krastel, EK Schmitt, AS Omar, EA Creasey, AL Garner, S Mohammadi, DJ O'Connell, S Abubucker, TD Arthur, EA Franzosa, C Huttenhower, LO Murphy, HJ Haiser, H Vlamakis, …, RJ Xavier. Indoleacrylic Acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe 2017; 22, 25-37.
Q Qi, J Li, B Yu, J Moon, JC Chai, J Merino, J Hu, M Ruiz-Canela, C Rebholz, Z Wang, M Usyk, G Chen, BC Porneala, W Wang, NQ Nguyen, EV Feofanova, ML Grove, TJ Wang, RE Gerszten, J Dupuis, …, RC Kaplan. Host and gut microbial tryptophan metabolism and type 2 diabetes: An integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies. Gut 2022; 71, 1095-105.
C Menni, MM Hernandez, M Vital, RP Mohney, TD Spcector and AM Valdes. Circulating levels of the anti-oxidant indoleproprionic acid are associated with higher gut microbiome diversity. Gut Microbes 2019; 10, 688-95.
F Magne, M Gotteland, L Gauthier, A Zazueta, S Pesoa, P Navarrete and R Balamurugan. The firmicutes/bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients? Nutrients 2020; 12, 1474.
W Ren, R Rajendran, Y Zhao, B Tan, G Wu, FW Bazer, G Zhu, Y Peng, X Huang, J Deng and Y Yin. Amino acids as mediators of metabolic cross talk between host and pathogen. Front. Immunol. 2018; 9, 319.
G Shanmuganathan, D Orujyan, W Narinyan, N Poladian, S Dhama, A Parthasarathy, A Ha, D Tran, P Velpuri, KH Nguyen and V Venketaraman. Role of interferons in mycobacterium tuberculosis infection. Clin. Pract. 2022; 12, 788-96.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
